Zealand Pharma A/S
Zealand Pharma A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to peptide-based therapeutics. Founded in 1998, the company has made significant strides in the biopharmaceutical industry, focusing on the development of novel treatments for diabetes, obesity, and gastrointestinal disorders. With a strong presence in Europe and North America, Zealand Pharma is committed to advancing its core products, which include unique peptide therapies that offer targeted solutions for complex health issues. The company has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its position as a key player in the global biopharmaceutical market. Zealand Pharma's dedication to scientific excellence and patient-centric solutions continues to drive its growth and impact in the healthcare landscape.
DitchCarbon Score
How does Zealand Pharma A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zealand Pharma A/S's score of 29 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zealand Pharma A/S's reported carbon emissions
In 2023, Zealand Pharma A/S reported total carbon emissions of approximately 73,923,000 kg CO2e. This figure includes 144,000 kg CO2e from Scope 1 emissions, 23,000 kg CO2e from Scope 2 (market-based), and a significant 73,757,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by investments (52,446,000 kg CO2e), purchased goods and services (19,484,000 kg CO2e), and downstream transportation and distribution (747,000 kg CO2e). For 2024, the company’s total emissions increased to about 266,557,000 kg CO2e, with Scope 1 emissions at 145,000 kg CO2e, Scope 2 emissions at 17,000 kg CO2e (location-based), and a substantial 266,412,000 kg CO2e from Scope 3. The major contributors to Scope 3 emissions included investments (221,492,000 kg CO2e) and purchased goods and services (42,712,000 kg CO2e). Despite these figures, Zealand Pharma has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments or reduction strategies suggests a need for further action in addressing their environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 144,000 | 000,000 |
| Scope 2 | 23,000 | - |
| Scope 3 | 73,757,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zealand Pharma A/S is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
